{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:43:03Z","timestamp":1788874983965,"version":"build-2803163510"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Charles Darwin International PhD Scholarships"},{"name":"NHMRC Investigator Grant","award":["2008501"],"award-info":[{"award-number":["2008501"]}]},{"name":"NHMRC Investigator Grant","award":["2033264"],"award-info":[{"award-number":["2033264"]}]},{"name":"Australian National Health and Medical Research Council","award":["1182950"],"award-info":[{"award-number":["1182950"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-025-05525-0","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:44:12Z","timestamp":1759236252000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Perceptions of shorter radical cure Plasmodium vivax treatment regimens and their implementation: a qualitative study among stakeholders in Cambodia"],"prefix":"10.1186","volume":"24","author":[{"given":"Sarah A.","family":"Cassidy-Seyoum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keoratha","family":"Chheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phal","family":"Chanpheakdey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Meershoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Hsiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"von Seidlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupam","family":"Tripura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Ley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ric N.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dysoley","family":"Lek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamala","family":"Thriemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"5525_CR1","volume-title":"World malaria report 2023","author":"WHO","year":"2023","unstructured":"WHO. World malaria report 2023. Geneva: World Health Organization; 2023."},{"key":"5525_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003561","volume":"18","author":"CS Chu","year":"2021","unstructured":"Chu CS, White NJ. The prevention and treatment of Plasmodium vivax malaria. PLoS Med. 2021;18: e1003561.","journal-title":"PLoS Med"},{"key":"5525_CR3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0140-6736(19)31096-7","volume":"394","author":"KE Battle","year":"2019","unstructured":"Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000\u201317: a spatial and temporal modelling study. Lancet. 2019;394:332\u201343.","journal-title":"Lancet"},{"key":"5525_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1475-2875-11-135","volume":"11","author":"NM Douglas","year":"2012","unstructured":"Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, White NJ, et al. The anaemia of Plasmodium vivax malaria. Malar J. 2012;11:135.","journal-title":"Malar J"},{"key":"5525_CR5","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1086\/599041","volume":"48","author":"JR Poespoprodjo","year":"2009","unstructured":"Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, et al. Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis. 2009;48:1704\u201312.","journal-title":"Clin Infect Dis"},{"key":"5525_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1186\/1475-2875-13-481","volume":"13","author":"BA Rahimi","year":"2014","unstructured":"Rahimi BA, Thakkinstian A, White NJ, Sirivichayakul C, Dondorp AM, Chokejindachai W. Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900. Malar J. 2014;13:481.","journal-title":"Malar J"},{"key":"5525_CR7","doi-asserted-by":"publisher","first-page":"828","DOI":"10.2471\/BLT.18.226688","volume":"97","author":"A Devine","year":"2019","unstructured":"Devine A, Pasaribu AP, Teferi T, Pham HT, Awab GR, Contantia F, et al. Provider and household costs of Plasmodium vivax malaria episodes: a multicountry comparative analysis of primary trial data. Bull World Health Organ. 2019;97:828\u201336.","journal-title":"Bull World Health Organ"},{"key":"5525_CR8","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0140-6736(19)31285-1","volume":"394","author":"WRJ Taylor","year":"2019","unstructured":"Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 2019;394:929\u201338.","journal-title":"Lancet"},{"key":"5525_CR9","first-page":"542","volume":"8","author":"NJ White","year":"2010","unstructured":"White NJ, Pukrittayakamee S, Chotivanich K, Day NPJ, Imwong M, Singhasivanon P. A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. Am J Trop Med Hyg. 2010;8:542\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"5525_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1710775","volume":"380","author":"MVG Lacerda","year":"2019","unstructured":"Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, et al. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380:215\u201328.","journal-title":"N Engl J Med"},{"key":"5525_CR11","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(13)62568-4","volume":"383","author":"A Llanos-Cuentas","year":"2014","unstructured":"Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383:1049\u201358.","journal-title":"Lancet"},{"key":"5525_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa1802537","volume":"380","author":"A Llanos-Cuentas","year":"2019","unstructured":"Llanos-Cuentas A, Lacerda MVG, Hien TT, V\u00e9lez ID, Namaik-larp C, Chu CS, et al. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380:229\u201341.","journal-title":"N Engl J Med"},{"key":"5525_CR13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/pathogens12050650","volume":"12","author":"A Sadhewa","year":"2023","unstructured":"Sadhewa A, Cassidy-Seyoum S, Acharya S, Devine A, Price RN, Mwaura M, et al. A review of the current status of G6PD deficiency testing to guide radical cure treatment for vivax malaria. Pathogens. 2023;12:650.","journal-title":"Pathogens"},{"key":"5525_CR14","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd edn. Geneva: World Health Organization; 2015, p. 313. https:\/\/apps.who.int\/iris\/handle\/10665\/162441 Accessed 14 Dec 2021."},{"key":"5525_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12936-018-2380-8","volume":"17","author":"K Thriemer","year":"2018","unstructured":"Thriemer K, Bobogare A, Ley B, Gudo CS, Alam MS, Anstey NM, et al. Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group. Malar J. 2018;17:241.","journal-title":"Malar J"},{"key":"5525_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12936-017-1784-1","volume":"16","author":"K Thriemer","year":"2017","unstructured":"Thriemer K, Ley B, Bobogare A, Dysoley L, Alam MS, Pasaribu AP, et al. Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN vivax working group. Malar J. 2017;16:141.","journal-title":"Malar J"},{"key":"5525_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1473-3099(23)00430-9","volume":"24","author":"RJ Commons","year":"2024","unstructured":"Commons RJ, Rajasekhar M, Edler P, Abreha T, Awab GR, Baird JK, et al. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2024;24:172\u201383.","journal-title":"Lancet Infect Dis"},{"key":"5525_CR18","unstructured":"WHO. Guidelines for malaria. Geneva: World Health Organization; 2023. https:\/\/www.who.int\/publications\/i\/item\/guidelines-for-malaria\/. Accessed 12 May 2023."},{"key":"5525_CR19","unstructured":"WHO. Guidelines for malaria 2024. Geneva: World Health Organization; 2024. https:\/\/iris.who.int\/handle\/10665\/379635. Accessed 13 Dec 2024."},{"key":"5525_CR20","unstructured":"National Center for Parasitology, Entomology and Malaria Control (CNM). National Treatment Guidelines for Malaria in Cambodia. Ministry of Health; 2022."},{"key":"5525_CR21","unstructured":"Center of Malariology, Parasitology and Entomology. Lao PDR National Guidelines for the Treatment of Malaria. Ministry of Health Lao PDR; 2022."},{"key":"5525_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13071-023-06058-8","volume":"17","author":"H Liu","year":"2024","unstructured":"Liu H, Xu JW, Deng DW, Yaw B, Nbwi HS, Wei C, et al. Artemisinin-naphthoquine plus lower-dose primaquine to treat and prevent recurrence of Plasmodium vivax malaria: an open-label randomized and non-inferiority trial. Parasit Vectors. 2024;17:28.","journal-title":"Parasit Vectors"},{"key":"5525_CR23","unstructured":"GSK. Brazil and Thailand become first malaria-endemic countries to launch new single-dose radical cure medicine to prevent the relapse of Plasmodium vivax malaria. 2024. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/brazil-and-thailand-become-first-malaria-endemic-countries-to-launch-new-single-dose-radical-cure-medicine\/#:~:text=Approvals%20for%20tafenoquine%20have%20been,vivax%20is%20endemic. Accessed 11 Dec 2024."},{"key":"5525_CR24","unstructured":"Medicines for Malaria Venture. Tafenoquine. 2024. www.mmv.org\/mmv-pipeline-antimalarial-drugs\/tafenoquine. Accessed 12 Dec 2024."},{"key":"5525_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(08)60073-2","volume":"371","author":"M Cappellini","year":"2008","unstructured":"Cappellini M, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371:64\u201374.","journal-title":"Lancet"},{"key":"5525_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001339","volume":"9","author":"RE Howes","year":"2012","unstructured":"Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9: e1001339.","journal-title":"PLoS Med"},{"key":"5525_CR27","unstructured":"WHO. Guide to G6PD deficiency rapid diagnostic testing to support P. vivax radical cure. 2018; https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/272971\/9789241514286-eng.pdf"},{"key":"5525_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijid.2023.03.010","volume":"130","author":"SA Woon","year":"2023","unstructured":"Woon SA, Moore BR, Laman M, Tesine P, Lorry L, Kasian B, et al. Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: a randomized, open-label, non-inferiority trial of early versus delayed treatment. Int J Infect Dis. 2023;130:189\u201395.","journal-title":"Int J Infect Dis"},{"key":"5525_CR29","unstructured":"Cassidy-Seyoum S. Informing implementation strategies for the safe provision of high dose short course primaquine and tafenoquine. Oral Presentation presented at: ASTMH; 2024 Nov 17; New Orleans."},{"key":"5525_CR30","unstructured":"Minist\u00e9rio da Sa\u00fade, Secretaria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Imuniza\u00e7\u00e3o e Doen\u00e7as Transmiss\u00edveis. Guia de tratamento da mal\u00e1ria no Brasil]. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2020. http:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/guia_tratamento_malaria_brasil.pdf. Accessed 9 Apr 2025."},{"key":"5525_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2025-019615","volume":"10","author":"SA Cassidy-Seyoum","year":"2025","unstructured":"Cassidy-Seyoum SA, Adhikari B, Chheng K, Chanpheakdey P, Meershoek A, Hsiang MS, et al. Acceptability and feasibility of glucose-6-phosphate dehydrogenase (G6PD) testing using SD biosensor by village malaria workers in Cambodia: a qualitative study. BMJ Glob Health. 2025;10: e019615.","journal-title":"BMJ Glob Health"},{"key":"5525_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-8-22","volume":"8","author":"SR Chaudoir","year":"2013","unstructured":"Chaudoir SR, Dugan AG, Barr CH. Measuring factors affecting implementation of health innovations: a systematic review of structural, organizational, provider, patient, and innovation level measures. Implement Sci. 2013;8: 22.","journal-title":"Implement Sci"},{"key":"5525_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5772\/61114","volume":"2","author":"E Miller","year":"2015","unstructured":"Miller E, Sikes HD. Addressing barriers to the development and adoption of rapid diagnostic tests in global health. Nanobiomedicine. 2015;2:6.","journal-title":"Nanobiomedicine"},{"key":"5525_CR34","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1186\/s12913-016-1834-3","volume":"16","author":"CHD Jones","year":"2016","unstructured":"Jones CHD, Glogowska M, Locock L, Lasserson DS. Embedding new technologies in practice \u2013 a normalization process theory study of point of care testing. BMC Health Serv Res. 2016;16:591.","journal-title":"BMC Health Serv Res"},{"key":"5525_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135112","volume":"10","author":"N Engel","year":"2015","unstructured":"Engel N, Ganesh G, Patil M, Yellappa V, Pant Pai N, Vadnais C, et al. Barriers to point-of-care testing in India: results from qualitative research across different settings, users and major diseases. PLoS ONE. 2015;10: e0135112.","journal-title":"PLoS ONE"},{"key":"5525_CR36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.23987\/sts.63085","volume":"30","author":"N Engel","year":"2017","unstructured":"Engel N, Yellappa V, Pant Pai N, Pai M. Diagnosing at point of care in South India. Sci Technol Stud. 2017;30:54\u201372.","journal-title":"Sci Technol Stud"},{"key":"5525_CR37","unstructured":"Kingdom of Cambodia, Ministry of Health. Cambodia Malaria Elimination Action Framework 2021\u20132025. Kingdom of Cambodia Ministry of Health; 2020. https:\/\/www.cnm.gov.kh\/index.php?action=ID6"},{"key":"5525_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-020-03482-4","volume":"19","author":"M Sandfort","year":"2020","unstructured":"Sandfort M, Vantaux A, Kim S, Obadia T, Pepey A, Gardais S, et al. Forest malaria in Cambodia: the occupational and spatial clustering of Plasmodium vivax and Plasmodium falciparum infection risk in a cross-sectional survey in Mondulkiri province, Cambodia. Malar J. 2020;19: 413.","journal-title":"Malar J"},{"key":"5525_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12936-019-2666-5","volume":"18","author":"SD Nofal","year":"2019","unstructured":"Nofal SD, Peto TJ, Adhikari B, Tripura R, Callery J, Bui TM, et al. How can interventions that target forest-goers be tailored to accelerate malaria elimination in the Greater Mekong Subregion? A systematic review of the qualitative literature. Malar J. 2019;18:32.","journal-title":"Malar J"},{"key":"5525_CR40","unstructured":"WHO. Mekong Malaria Elimination\u00a0: epidemiology summary, volume 13, January-March, 2021. World Health Organization; 2021."},{"key":"5525_CR41","unstructured":"WHO. Mekong Malaria Elimination: epidemiology summary; October - December 2022. Geneva, World Health Organization; 2023. https:\/\/iris.who.int\/bitstream\/handle\/10665\/366565\/WHO-UCN-GMP-MME-2023.01-eng.pdf?sequence=1"},{"key":"5525_CR42","unstructured":"WHO Mekong malaria elimination: epidemiology summary, volume 24, October\u2013December 2023. Geneva, World Health Organization; 2024. https:\/\/www.who.int\/publications\/i\/item\/B09068. Accessed 26 Jul 2024."},{"key":"5525_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028357","volume":"6","author":"S Kim","year":"2011","unstructured":"Kim S, Nguon C, Guillard B, Duong S, Chy S, Sum S, et al. Performance of the CareStart\u2122 G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening. PLoS ONE. 2011;6: e28357.","journal-title":"PLoS ONE"},{"key":"5525_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116143","volume":"9","author":"A Roca-Feltrer","year":"2014","unstructured":"Roca-Feltrer A, Khim N, Kim S, Chy S, Canier L, Kerleguer A, et al. Field trial evaluation of the performances of point-of-care tests for screening G6PD deficiency in Cambodia. PLoS ONE. 2014;9: e116143.","journal-title":"PLoS ONE"},{"key":"5525_CR45","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s10038-005-0279-z","volume":"50","author":"H Matsuoka","year":"2005","unstructured":"Matsuoka H, Nguon C, Kanbe T, Jalloh A, Sato H, Yoshida S, et al. Glucose-6-phosphate dehydrogenase (G6PD) mutations in Cambodia: G6PD Viangchan (871G>A) is the most common variant in the Cambodian population. J Hum Genet. 2005;50:468\u201372.","journal-title":"J Hum Genet"},{"key":"5525_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12936-019-2652-y","volume":"18","author":"G Bancone","year":"2019","unstructured":"Bancone G, Menard D, Khim N, Kim S, Canier L, Nguong C, et al. Molecular characterization and mapping of glucose-6-phosphate dehydrogenase (G6PD) mutations in the Greater Mekong Subregion. Malar J. 2019;18:20.","journal-title":"Malar J"},{"key":"5525_CR47","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4103\/2224-3151.213793","volume":"6","author":"S Kitchakarn","year":"2017","unstructured":"Kitchakarn S, Lek D, Thol S, Hok C, Saejeng A, Huy R, et al. Implementation of G6PD testing and primaquine for P. vivax radical cure: operational perspectives from Thailand and Cambodia. WHO South-East Asia J Public Health. 2017;6:60\u20138.","journal-title":"WHO South-East Asia J Public Health"},{"key":"5525_CR48","unstructured":"Ministry of Health Cambodia. Malaria Information System (DHIS2)."},{"key":"5525_CR49","unstructured":"U.S. National Library of Medicine. Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine. National Institute of Health; https:\/\/clinicaltrials.gov\/study\/NCT04411836. Accessed 19 Jan 2024."},{"key":"5525_CR50","unstructured":"UN OCHA. Cambodia - Subnational Administrative Boundaries [Internet]. Humanitarian Data Exchange; 2018. https:\/\/data.humdata.org\/dataset\/cod-ab-khm. Accessed 24 Jul 2024."},{"key":"5525_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0003476","volume":"4","author":"SA Cassidy-Seyoum","year":"2024","unstructured":"Cassidy-Seyoum SA, Chheng K, Chanpheakdey P, Meershoek A, Hsiang MS, von Seidlein L, et al. Implementation of Glucose-6-Phosphate Dehydrogenase (G6PD) testing for Plasmodium vivax case management, a mixed method study from Cambodia. PLoS Glob Public Health. 2024;4: e0003476.","journal-title":"PLoS Glob Public Health"},{"key":"5525_CR52","doi-asserted-by":"crossref","unstructured":"Cassidy-Seyoum SA, Chheng K, Chanpheakdey P, Meershoek A, Hsiang MS, Von Seidlein L, et al. Community patient follow-up as a part of P. vivax case management in Cambodia: a mixed methods study. 2025. https:\/\/www.researchsquare.com\/article\/rs-6423610\/v1. Accessed 16 May 2025.","DOI":"10.21203\/rs.3.rs-6423610\/v1"},{"key":"5525_CR53","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12936-025-05425-3","volume":"24","author":"SA Cassidy-Seyoum","year":"2025","unstructured":"Cassidy-Seyoum SA, Mwaura M, Chheng K, Kejela M, Korra KG, Wodaj T, et al. Co-design of a routine clinical review to improve the safety of high dose radical cure treatment for Plasmodium vivax malaria: findings from Cambodia and Ethiopia. Malar J. 2025;24:171.","journal-title":"Malar J"},{"key":"5525_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116856","volume":"10","author":"S Chatio","year":"2015","unstructured":"Chatio S, Aborigo R, Adongo PB, Anyorigiya T, Akweongo P, Oduro A. Adherence and uptake of artemisinin-based combination treatments for uncomplicated malaria: a qualitative study in Northern Ghana. PLoS ONE. 2015;10: e0116856.","journal-title":"PLoS ONE"},{"key":"5525_CR55","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1046\/j.1365-3156.2002.00919.x","volume":"7","author":"B Reilley","year":"2002","unstructured":"Reilley B, Abeyasinghe R, Pakianathar MV. Barriers to prompt and effective treatment of malaria in northern Sri Lanka. Trop Med Int Health. 2002;7:744\u20139.","journal-title":"Trop Med Int Health"},{"issue":"1","key":"5525_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06851-9","volume":"21","author":"A Twimukye","year":"2021","unstructured":"Twimukye A, Laker M, Odongpiny EAL, Ajok F, Onen H, Kalule I, et al. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda. BMC Infect Dis. 2021;21(1): 1154.","journal-title":"BMC Infect Dis"},{"key":"5525_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150849","volume":"11","author":"KS Shringarpure","year":"2016","unstructured":"Shringarpure KS, Isaakidis P, Sagili KD, Baxi RK, Das M, Daftary A. \u201cWhen treatment is more challenging than the disease\u201d: a qualitative study of MDR-TB patient retention. PLoS ONE. 2016;11: e0150849.","journal-title":"PLoS ONE"},{"key":"5525_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-023-04578-3","volume":"22","author":"A Rahmalia","year":"2023","unstructured":"Rahmalia A, Poespoprodjo JR, Landuwulang CUR, Ronse M, Kenangalem E, Burdam FH, et al. Adherence to 14-day radical cure for Plasmodium vivax malaria in Papua, Indonesia: a mixed-methods study. Malar J. 2023;22: 162.","journal-title":"Malar J"},{"issue":"6 Suppl","key":"5525_CR59","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4269\/ajtmh.16-0208","volume":"95","author":"S Siv","year":"2016","unstructured":"Siv S, Roca-Feltrer A, Vinjamuri SB, Bouth DM, Lek D, Rashid MA, et al. Plasmodium vivax malaria in Cambodia. Am J Trop Med Hyg. 2016;95(6 Suppl):97\u2013107.","journal-title":"Am J Trop Med Hyg"},{"key":"5525_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-469","volume":"14","author":"\u00c1 Lubl\u00f3y","year":"2014","unstructured":"Lubl\u00f3y \u00c1. Factors affecting the uptake of new medicines: a systematic literature review. BMC Health Serv Res. 2014;14: 469.","journal-title":"BMC Health Serv Res"},{"key":"5525_CR61","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12936-017-1854-4","volume":"16","author":"C Pell","year":"2017","unstructured":"Pell C, Tripura R, Nguon C, Cheah P, Davoeung C, Heng C, et al. Mass anti-malarial administration in western Cambodia: a qualitative study of factors affecting coverage. Malar J. 2017;16:206.","journal-title":"Malar J"},{"key":"5525_CR62","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s41182-024-00607-2","volume":"52","author":"D Lek","year":"2024","unstructured":"Lek D, Sokomar N, Samphornarann T, Rideout J, Hassan SED, Bunkea T, et al. Impact of targeted drug administration and intermittent preventive treatment for forest goers using artesunate\u2013pyronaridine to control malaria outbreaks in Cambodia. Trop Med Health. 2024;52:42.","journal-title":"Trop Med Health"},{"key":"5525_CR63","unstructured":"Najia Ghanchi. Safety of unsupervised high dose short course primaquine and tafenoquine\u200b. Symposium Presentation presented at: ASTMH; 2024 Nov 17; New Orleans."},{"key":"5525_CR64","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s13256-016-1091-4","volume":"10","author":"M Jain","year":"2016","unstructured":"Jain M, Nevin RL, Ahmed I. Mefloquine-associated dizziness, diplopia, and central serous chorioretinopathy: a case report. J Med Case Rep. 2016;10:305.","journal-title":"J Med Case Rep"},{"key":"5525_CR65","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12936-024-05209-1","volume":"23","author":"APC Santos","year":"2024","unstructured":"Santos APC, Brito MAM, Oliveira APS, D\u00e1vila RN, Gama HSS, Silva EART, et al. Assessing tafenoquine implementation in Brazil: a qualitative evaluation of perceptions of healthcare providers and Plasmodium vivax patients (QualiTRuST study). Malar J. 2024;23:399.","journal-title":"Malar J"},{"key":"5525_CR66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12936-024-05233-1","volume":"24","author":"E Lufele","year":"2025","unstructured":"Lufele E, Pascoe S, Mengi A, Auwun A, Neuendorf N, Bolnga JW, et al. Acceptability of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine plus dihydroartemisinin-piperaquine in Papua New Guinea: a qualitative study. Malar J. 2025;24:13.","journal-title":"Malar J"},{"key":"5525_CR67","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1186\/s12889-024-20748-7","volume":"24","author":"J Ondiro","year":"2024","unstructured":"Ondiro J, Onyangore F, Onyango R, Muema L, Aduda DSO. Lived experiences of persons on tuberculosis treatment in Nairobi County, Kenya: a mixed methods study. BMC Public Health. 2024;24:3440.","journal-title":"BMC Public Health"},{"key":"5525_CR68","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/inthealth\/ihad104","volume":"16","author":"O Chijioke-Akaniro","year":"2024","unstructured":"Chijioke-Akaniro O, Akinyemi PA, Asuke S, Anyaike C, Uwaezuoke NA, Ochuko U, et al. Influence of the new dispersible fixed-dose combination anti-tuberculosis drug on treatment adherence among children with Tuberculosis in Osun State, Nigeria. Int Health. 2024;16:534\u201343.","journal-title":"Int Health"},{"key":"5525_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0011332","volume":"17","author":"S McPherson","year":"2023","unstructured":"McPherson S, Geleta D, Tafese G, Tafese T, Behaksira S, Solomon H, et al. Perceptions and acceptability of co-administered albendazole, ivermectin and azithromycin mass drug administration, among the health workforce and recipient communities in Ethiopia. PLoS Negl Trop Dis. 2023;17: e0011332.","journal-title":"PLoS Negl Trop Dis"},{"key":"5525_CR70","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1177\/09564624241306158","volume":"36","author":"JR Espera","year":"2025","unstructured":"Espera JR, Reyes CA, Sarmiento EG, Sitchon CM, Zantua R, Carandang RR. Acceptability and feasibility of HIV pre-exposure prophylaxis (PrEP) in Southeast Asia: a scoping review. Int J STD AIDS. 2025;36:260\u201374.","journal-title":"Int J STD AIDS"},{"key":"5525_CR71","doi-asserted-by":"publisher","first-page":"232595822110005","DOI":"10.1177\/23259582211000517","volume":"20","author":"JM Simoni","year":"2021","unstructured":"Simoni JM, Beima-Sofie K, Wanje G, Mohamed ZH, Tapia K, McClelland RS, et al. \u201cLighten this burden of ours\u201d: acceptability and preferences regarding injectable antiretroviral treatment among adults and youth living With HIV in Coastal Kenya. J Int Assoc Provid AIDS Care. 2021;20:23259582211000516.","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"5525_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-025-12265-z","volume":"25","author":"N Mphothulo","year":"2025","unstructured":"Mphothulo N, Hlangu S, Furin J, Moshabela M, Loveday M. Navigating DR-TB treatment care: a qualitative exploration of barriers and facilitators to retention in care among people with history of early disengagement from drug-resistant tuberculosis treatment in Johannesburg, South Africa. BMC Health Serv Res. 2025;25: 122.","journal-title":"BMC Health Serv Res"},{"key":"5525_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2023.100385","volume":"33","author":"R Nabisere-Arinaitwe","year":"2023","unstructured":"Nabisere-Arinaitwe R, Namatende-Sakwa L, Bayiga J, Nampala J, Alinaitwe L, Aber F, et al. \u201cIt is not easy\u201d: experiences of people living with HIV and tuberculosis on Tuberculosis treatment in Uganda. J Clin Tuberc Other Mycobact Dis. 2023;33: 100385.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"5525_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2024-017368","volume":"10","author":"S Mwima","year":"2025","unstructured":"Mwima S, Bogart LM, Musoke W, Mukama SC, Allupo S, Kadama H, et al. Applying implementation science frameworks to understand why fisherfolk continue or discontinue pre-exposure prophylaxis for HIV prevention in Uganda: a qualitative analysis. BMJ Glob Health. 2025;10: e017368.","journal-title":"BMJ Glob Health"},{"key":"5525_CR75","unstructured":"GSK. KRINTAFEL (tafenoquine) Tablets Perscribing Information. 2023. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Krintafel\/pdf\/KRINTAFEL-PI-PIL.PDF. Accessed 9 Mar 2025."},{"key":"5525_CR76","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S1473-3099(23)00213-X","volume":"23","author":"I Sutanto","year":"2023","unstructured":"Sutanto I, Soebandrio A, Ekawati LL, Chand K, Noviyanti R, Satyagraha AW, et al. Tafenoquine co-administered with dihydroartemisinin\u2013piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study. Lancet Infect Dis. 2023;23:1153\u201363.","journal-title":"Lancet Infect Dis"},{"key":"5525_CR77","doi-asserted-by":"publisher","first-page":"152","DOI":"10.5694\/mja2.50474","volume":"212","author":"RJ Commons","year":"2020","unstructured":"Commons RJ, McCarthy JS, Price RN. Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency. Med J Aust. 2020;212:152.","journal-title":"Med J Aust"},{"key":"5525_CR78","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12936-024-05050-6","volume":"23","author":"TH Barker","year":"2024","unstructured":"Barker TH, McBride GM, Dias M, Price C, Munn Z. Contextual factors and G6PD diagnostic testing: a scoping review and evidence and gap map. Malar J. 2024;23:241.","journal-title":"Malar J"},{"key":"5525_CR79","unstructured":"Emily GG, Sarah CS, Huygen N. Integrating G6PD point-of-care testing into malaria case management to support radical cure: an assessment of health worker skills and knowledge in Laos and Vietnam. Poster Session presented at: ASTMH; 2021; Online."},{"key":"5525_CR80","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12936-021-03743-w","volume":"20","author":"N Engel","year":"2021","unstructured":"Engel N, Ghergu C, Matin MA, Kibria MG, Thriemer K, Price RN, et al. Implementing radical cure diagnostics for malaria: user perspectives on G6PD testing in Bangladesh. Malar J. 2021;20:217.","journal-title":"Malar J"},{"key":"5525_CR81","volume":"9","author":"B Adhikari","year":"2023","unstructured":"Adhikari B, Tripura R, Peto TJ, Callery JJ, Von Seidlein L, Dysoley L, et al. Village malaria workers for the community-based management of vivax malaria. Lancet Reg Health. 2023;9: 100128.","journal-title":"Lancet Reg Health"},{"key":"5525_CR82","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1473-3099(23)00431-0","volume":"24","author":"M Rajasekhar","year":"2024","unstructured":"Rajasekhar M, Simpson JA, Ley B, Edler P, Chu CS, Abreha T, et al. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2024;24:184\u201395.","journal-title":"Lancet Infect Dis"},{"key":"5525_CR83","doi-asserted-by":"publisher","first-page":"761","DOI":"10.4269\/ajtmh.23-0280","volume":"109","author":"D Yilma","year":"2023","unstructured":"Yilma D, Groves ES, Brito-Sousa JD, Monteiro WM, Chu C, Thriemer K, et al. Severe hemolysis during primaquine radical cure of Plasmodium vivax malaria: two systematic reviews and individual patient data descriptive analyses. Am J Trop Med Hyg. 2023;109:761\u20139.","journal-title":"Am J Trop Med Hyg"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05525-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05525-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05525-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T01:03:00Z","timestamp":1759280580000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05525-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5525"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05525-0","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Cambodian National Ethics Board (# 118) and the Institutional Review Board of the Menzies School of Health Research (HREC 2020-3694). Participants provided written informed consent. All data were anonymized.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"304"}}